Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

Dose-response Relationship of Five Dose Levels of NNC90-1170 and Placebo on Glycaemic Control in Type 2 Diabetic Patients Compared to OHA Treatment. A 12-week Multi-centre, Double-blind, Randomised, Parallel Group Trial With an Open Labelled OHA Arm

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01509755

Enrollment

196

Registered

2012-01-13

Start date

2000-10-31

Completion date

2001-10-31

Last updated

2017-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This trial is conducted in Europe. The aim of this trial is to establish the dose response relationship on glycaemic control of five dose levels of NNC90-1170.

Interventions

DRUGplacebo

Once daily injection, under the skin (s.c.) for 12 weeks

DRUGliraglutide

Once daily injection, under the skin (s.c.) for 12 weeks

DRUGglimepiride

Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response

Eligibility

Sex/Gender

ALL

Age

30 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Subjects with type 2 diabetes * Duration of diabetes at least 3 months * Both diet treated and patients in therapy with OHA (oral hypoglycemic agents) * Body Mass Index maximum 40 kg/m\^2 * HbA1c based on analysis from central laboratory: Between 7.5-10.0%, both inclusive, for diet treated, or maximum 9.0% for OHA treated

Exclusion criteria

* Liver or renal disease * Cardiac problems * Uncontrolled treated/untreated hypertension * Proliferative retinopathy * Recurrent severe hypoglycaemia as judged by the Investigator * Known or suspected allergy to trial product or related products * Use of any drug (except for OHAs) which in the Investigator's opinion could interfere with the blood glucose level

Design outcomes

Primary

Measure	Time frame
HbA1c (glycosylated haemoglobin)	—

Secondary

Measure	Time frame
Fasting plasma glucose	—
Fructosamine	—
7-point blood glucose profile	—
Adverse events	—

Countries

Denmark, Norway, Sweden, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026